| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Careers Employment > State Employee Incentive Programs |
|
Digg It - State Employee Incentive Programs
Industrial workers are paid compensation for their services in the form of wages. Wages are fixed as the According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product time spent by the worker in the factory or per the production produced. Wage is a matter of great impor ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ance as most of the labor problems are related to wage payment. The efficiency of workers and their inte lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. rest and development in their work depend on wages. Their attitude towards their employer is influenced here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe y how fairly they thing they are being paid. Wages are important to employers because their profit depe d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro nds on total wages billed. An employer, in general, is interested in paying as low wages as possible. Ho ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc ever, low wages are not necessarily economical. In fact, they may prove to be too costly to the employer easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi . An employer has a moral and social responsibility to pay fair wages to the workers, as they are the pa nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically tners in the productive process. The employer should introduce an incentive wage system that will benefi and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ t both employer and employee. There are basically two types of incentives – financial and non-financial ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi Financial incentives help individuals meet their basic needs and non-financial incentives assist in mee ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ting the higher order needs such as social, esteem and self-actualization needs. Non-financial incentive dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod are based on sociological and psychological principles of higher behavior. Some of the important objec cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin tives for which incentive programs are used are to increase production, productivity, yield, manpower ut tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen lization, and earnings of employees, sales and quality. Incentive programs also play a major role in imp t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel roving quality, reduced cost of production, reduced inventory and reduced wastage. Financial incentive ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust chemes can be direct or indirect in nature. In direct financial incentive schemes, the payments are base y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products d on an employee’s performance or contribution to the job such as production incentive schemes, attendan . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de e bonus, etc. In the case of indirect financial incentives, the payments are not directly related to emp elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip loyee contribution. Leave encashment, gratuity schemes and leave travel concession fall in this category tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:The Top 5 Business and Consumer Telecom Scams Matching Advertising Gifts To The Client
|